Trailblaze Pharos regulatory update
Ignyta said it received CE Mark approval for its Trailblaze Pharos companion diagnostic to identify patients who have solid tumors with neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1), TrkB, TrkC, c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) or anaplastic lymphoma kinase (ALK) gene rearrangements leading to fusion proteins. Trailblaze Pharos is the proposed companion diagnostic for Ignyta’s entrectinib (formerly RXDX-101), which is in Phase II testing to treat patients with solid tumors harboring TrkA, TrkB, TrkC, ROS1 or ALK gene rearrangements. The product is an oral inhibitor of the mutations...
BCIQ Company Profiles